Dr. Michael D Evans-zepeda, PSY.D. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 13200 Crossroads Pkwy N Ste 350, City Of Industry, CA 91746 Phone: 562-821-1491 |
Masha Manko Psychologist - Clinical Child & Adolescent Medicare: Not Enrolled in Medicare Practice Location: 13200 Crossroads Pkwy N, City Of Industry, CA 91746 Phone: 562-821-9603 |
Cynthia Bautista Psychologist Medicare: Not Enrolled in Medicare Practice Location: 13200 Crossroads Pkwy N, City Of Industry, CA 91746 Phone: 562-821-1491 |
Goldie Jasmine Barajas Psychologist Medicare: Not Enrolled in Medicare Practice Location: 13200 Crossroads Pkwy N Ste 335, City Of Industry, CA 91746 Phone: 562-821-1491 |
Dr. Yadira Vazquez, PSYD Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 13200 Crossroads Pkwy N Ste 335, City Of Industry, CA 91746 Phone: 787-502-5472 |
News Archive
The prevalence of preterm birth - the birth of an infant prior to 37 weeks of pregnancy - is a significant health problem that has increased over the past two decades. According to the Centers for Disease Control and Prevention, preterm birth affects nearly 500,000 babies each year, or one of every eight born in the U.S. While medical care has improved survival rates for preterm infants, questions remain about ways to positively impact the neurodevelopmental outcomes of preterm infants.
Sexual transmission of the Ebola virus could have a major impact on the dynamics of the disease, potentially reigniting an outbreak that has been contained by public health interventions, according to research by University of Georgia ecologists just published in the Royal Society journal Biology Letters.
By striking up the right rhythm in the right brain region at the right time, Brown University neuroscientists report in Nature Neuroscience that they managed to endow mice with greater touch sensitivity than other mice, making hard-to-perceive vibrations suddenly more vivid to them.
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., announced today that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for KYNAMRO (mipomersen sodium) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).
› Verified 9 days ago